Sign up for Pharming’s EGM 2020 Webinar
WebinarsPharming Group N.V. will hold it’s 2020 Extraordinary General Meeting (EGM) on 11 December 2020 at 14:00 CET.
Pharming Group Publicly Files Registration Statement with the U.S. SEC to Facilitate Listing of ADSs Representing Ordinary Shares on Nasdaq Global Market
Financial updatesPharming Group N.V., a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, today announces that it has publicly filed a registration statement with the U.S. Securities and Exchange Commission (the "SEC") in connection with a proposed listing of American Depositary Shares ("ADSs") representing the Company's ordinary shares of nominal value €0.01 each ("Ordinary Shares") on the Nasdaq Global Market ("Nasdaq").
Juergen Ernst to retire from Pharming’s Board of Supervisory Directors after more than 11 years of distinguished service
Operational updatesPharming Group N.V. today announces that its Vice-Chair, Juergen Ernst, has, for personal reasons, decided to retire from the Board of Supervisory Directors (BOSD), effective immediately. Ms. Debora Jorn, a member of the BOSD, will succeed Juergen as Vice-Chair.
Pharming announces commitment to build a new downstream manufacturing facility for RUCONEST®
Operational updatesPharming Group N.V. announces it has committed to building a new facility to expand the Company’s downstream processing capacity for its lead product, RUCONEST® (recombinant C1 esterase inhibitor (rhC1INH)).
Pharming appoints Jeroen Wakkerman as Chief Financial Officer
Operational updatesPharming Group N.V. announces the appointment of Jeroen Wakkerman as Chief Financial Officer (CFO), with effect from 16 November 2020.
Pharming convenes Extraordinary General Meeting of shareholders
Financial updatesPharming Group N.V. announces it will hold an Extraordinary General Meeting (EGM) of Shareholders on Friday 11 December 2020 at 14:00 CET.
Pharming Group reports financial results for the first nine months of 2020
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the nine months and third quarter ended 30 September 2020.
Pharming receives Orphan Drug Designation from the European Commission for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)
Operational updatesPharming Group N.V. today announces that the European Commission has granted orphan drug designation for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA).
Sign up now: Pharming’s Q3 Webinar
WebinarsOn the 29th of October at 19:00 Pharming’s CEO, Sijmen de Vries will discuss the recently published Q3 2020 financial results, provide a business update and insight into market developments. Submit your questions in advance to investor@pharming.com
Pharming announces the publication of data from a compassionate use program of RUCONEST® in COVID-19 patients in a peer-reviewed journal
Clinical trialsPharming Group N.V. today announces the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use program of five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor, conestat alfa) at the University Hospital Basel, Switzerland.